nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2015 | Review – Cancer Research

The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells

verfasst von: Lianqin Li, Ai-Qun Yu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The mammalian peroxiredoxin (PRX) family contains six members that provide antioxidant defense in different cell types by removing reactive oxygen species (ROS) through conserved active cysteines. Different from other members, PRX3 is predominantly located in mitochondria, a major apoptosis mediator. The purpose of this review is to summarize the findings on PRX3 concerning its role in ROS removal, apoptosis, and chemoresistance of cancer cells.

Methods

The relevant literature from PubMed and Medline databases is reviewed in this article (1994-2014).

Results

Because of fast growth and relatively low supply of oxygen in cancer cells, ROS production from mitochondria is exaggerated to an extent that overwhelms cellular antioxidant defenses resulting in oxidative stress. As an active responder to oxidative stress, PRX3 is accordingly up-regulated in cancer cells to remove cellular ROS and inhibit apoptosis, which provides a favorable microenvironment for cell proliferation.

Conclusion

Since most of chemotherapy or radiotherapy for cancers is through ROS increase and apoptotic induction, PRX3 might be involved in the chemotherapeutic resistance of cancers.

Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B, Goldwasser F (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41–48CrossRefPubMed

Araki M, Nanri H, Ejima K, Murasato Y, Fujiwara T, Nakashima Y, Ikeda M (1999) Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. J Biol Chem 274:2271–2278CrossRefPubMed

Bae SH, Woo HA, Sung SH, Lee HE, Lee SK, Kil IS, Rhee SG (2009) Induction of sulfiredoxin via an Nrf2-dependent pathway and hyperoxidation of peroxiredoxin III in the lungs of mice exposed to hyperoxia. Antioxid Redox Signal 11:937–948CrossRefPubMed

Bae SH, Sung SH, Lee HE, Kang HT, Lee SK, Oh SY, Woo HA, Kil IS, Rhee SG (2012) Peroxiredoxin III and sulfiredoxin together protect mice from pyrazole-induced oxidative liver injury. Antioxid Redox Signal 17:1351–1361PubMedCentralCrossRefPubMed

Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA (2011) Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 71:755–765PubMedCentralCrossRefPubMed

Brown KK, Eriksson SE, Arnér ES, Hampton MB (2008) Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. Free Radic Biol Med 45:494–502CrossRefPubMed

Brown KK, Cox AG, Hampton MB (2010) Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin. FEBS Lett 584:1257–1262CrossRefPubMed

Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG (1994) Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA 91:7017–7021PubMedCentralCrossRefPubMed

Chae HZ, Kim HJ, Kang SW, Rhee SG (1999) Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract 45:101–112CrossRefPubMed

Chang TS, Cho CS, Park S, Yu S, Kang SW, Rhee SG (2004a) a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem 279:41975–41984CrossRefPubMed

Chang TS, Jeong W, Woo HA, Lee SM, Park S, Rhee SG (2004b) Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 279:50994–51001CrossRefPubMed

Chen C, Cai S, Wang G, Cao X, Yang X, Luo X, Feng Y, Hu J (2013) c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1α. Biochem Biophys Res Commun 430:505–511CrossRefPubMed

Chiribau CB, Cheng L, Cucoranu IC, Yu YS, Clempus RE, Sorescu D (2008) FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts. J Biol Chem 283:8211–8217PubMedCentralCrossRefPubMed

Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, Kim JR (2002) Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22:3331–3335PubMed

Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, Bay BH (2010) Silencing the peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol 36:359–364PubMed

Cox AG, Brown KK, Arner ES, Hampton MB (2008a) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76:1097–1109CrossRefPubMed

Cox AG, Pullar JM, Hughes G, Ledgerwood EC, Hampton MB (2008b) Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis. Free Radic Biol Med 44:1001–1009CrossRefPubMed

Cunniff B, Benson K, Stumpff J, Newick K, Held P, Taatjes D, Joseph J, Kalyanaraman B, Heintz NH (2013) Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells. J Cell Physiol 228:835–845PubMedCentralCrossRefPubMed

De Simoni S, Goemaere J, Knoops B (2008) Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+. Neurosci Lett 433:219–224CrossRefPubMed

De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G (2001) Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 414:308–313CrossRefPubMed

Doe MR, Ascano JM, Kaur M, Cole MD (2012) Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res 72:949–957PubMedCentralCrossRefPubMed

Drechsel DA, Patel M (2010) Respiration-dependent H₂O₂ removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J Biol Chem 285:27850–27858PubMedCentralCrossRefPubMed

Duan J, Lang Y, Song C, Xiong J, Wang Y, Yan Y (2013) siRNA targeting of PRDX3 enhances cisplatin—induced apoptosis in ovarian cancer cells through the suppression of the NF–κB signaling pathway. Mol Med Rep 7:1688–1694PubMed

Fels DR, Koumenis C (2005) HIF-1alpha and p53: the ODD couple? Trends Biochem Sci 30:426–429CrossRefPubMed

Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A (2012) FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ 19:968–979PubMedCentralCrossRefPubMed

Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, Liu ET (2000) Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60:5922–5928PubMed

Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimo AV, Tonetti DA, Gartel AL (2010) Thiazole antibiotics against breast cancer. Cell Cycle 9:1214–1217CrossRefPubMed

Han S, Shen H, Jung M, Hahn BS, Jin BK, Kang I, Ha J, Choe W (2012) Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer. Oncol Lett 3:1275–1279PubMedCentralPubMed

Hanschmann EM, Lönn ME, Schütte LD, Funke M, Godoy JR, Eitner S, Hudemann C, Lillig CH (2010) Both thioredoxin 2 and glutaredoxin 2 contribute to the reduction of the mitochondrial 2-Cys peroxiredoxin Prx3. J Biol Chem 285:40699–40705PubMedCentralCrossRefPubMed

He HC, Zhu JG, Chen XB, Chen SM, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, Zhong WD (2012) MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett 586:2451–2458CrossRefPubMed

Hu JX, Gao Q, Li L (2013) Peroxiredoxin 3 is a novel marker for cell proliferation in cervical cancer. Biomed Rep 1:228–230PubMedCentralPubMed

Jäschke A, Mi H, Tropschug M (1998) Human T cell cyclophilin18 binds to thiol-specific antioxidant protein Aop1 and stimulates its activity. J Mol Biol 277:763–769CrossRefPubMed

Jensen KS, Binderup T, Jensen KT, Therkelsen I, Borup R, Nilsson E, Multhaupt H, Bouchard C, Quistorff B, Kjaer A, Landberg G, Staller P (2011) FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO J 30:4554–4570PubMedCentralCrossRefPubMed

Jeong HJ, Jeong HW, Song SS, Kang JW, Seo JH, Lee YH, Lee KS, Kim DW (2011) Upregulation of peroxiredeoxin III in the hippocampus of acute immobilization stress model rats and the Foxo3a-dependent expression in PC12 cells. Cell Mol Neurobiol 31:1041–1046CrossRefPubMed

Kalinina EV, Berezov TT, Shtil’ AA, Chernov NN, Glazunova VA, Novichkova MD, Nurmuradov NK (2012) Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med 153:878–881CrossRefPubMed

Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y (2003) Peroxiredoxins in breast carcinoma. Clin Cancer Res 9:3418–3424PubMed

Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, Park YM (2007) Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res 67:546–554CrossRefPubMed

Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S, Yoon K, Jung M, Choe W (2009) Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 21:1391–1396PubMed

Kim YS, Lee HL, Lee KB, Park JH, Chung WY, Lee KS, Sheen SS, Park KJ, Hwang SC (2011) Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean J Intern Med 26:304–313PubMedCentralCrossRefPubMed

Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196:316–323CrossRefPubMed

Lee SP, Hwang YS, Kim YJ, Kwon KS, Kim HJ, Kim K, Chae HZ (2001) Cyclophilin a binds to peroxiredoxins and activates its peroxidase activity. J Biol Chem 276:29826–29832CrossRefPubMed

Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, Poon WS, Ng HK (2013a) MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol 23:413–425CrossRefPubMed

Li L, Zhang YG, Chen CL (2013b) Anti-apoptotic role of peroxiredoxin III in cervical cancer cells. FEBS Open Bio. 3:51–54PubMedCentralCrossRefPubMed

Lin JY, Tserng KY, Chen CC, Lin LT, Tung TC (1970) Abrin and ricin: new anti-tumour substances. Nature 227:292–293CrossRefPubMed

Liu L, Yang C, Yuan J, Chen X, Xu J, Wei Y, Yang J, Lin G, Yu L (2005) RPK118, a PX domain-containing protein, interacts with peroxiredoxin-3 through pseudo-kinase domains. Mol Cells 19:39–45CrossRefPubMed

Liu X, Feng R, Du L (2010) The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett 584:3185–3192CrossRefPubMed

Madeira JM, Gibson DL, Kean WF, Klegeris A (2012) The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20:297–306CrossRefPubMed

Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42:872–881CrossRefPubMed

Masaki M, Ikeda A, Shiraki E, Oka S, Kawasaki T (2003) Mixed lineage kinase LZK and antioxidant protein-1 activate NF-kappaB synergistically. Eur J Biochem 270:76–83CrossRefPubMed

McDonald C, Muhlbauer J, Perlmutter G, Taparra K, Phelan SA (2014) Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity. Int J Oncol 45:219–226PubMed

Miranda-Vizuete A, Damdimopoulos AE, Spyrou G (2000) The mitochondrial thioredoxin system. Antioxid Redox Signal 2:801–810CrossRefPubMed

Miyamoto N, Izumi H, Miyamoto R, Kondo H, Tawara A, Sasaguri Y, Kohno K (2011) Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway. Investig Ophthalmol Vis Sci 52:1055–1063CrossRef

Mu ZM, Yin XY, Prochownik EV (2002) Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 277:43175–43184CrossRefPubMed

Newick K, Cunniff B, Preston K, Held P, Arbiser J, Pass H, Mossman B, Shukla A, Heintz N (2012) Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PLoS One 7:e39404PubMedCentralCrossRefPubMed

Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ (2001) Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21:2085–2090PubMed

Noh YH, Baek JY, Jeong W, Rhee SG, Chang TS (2009) Sulfiredoxin translocation into mitochondria plays a crucial role in reducing hyperoxidized peroxiredoxin III. J Biol Chem 284:8470–8477PubMedCentralCrossRefPubMed

Nonn L, Berggren M, Powis G (2003) Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 1:682–689PubMed

Obacz J, Pastorekova S, Vojtesek B, Hrstka R (2013) Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. Mol Cancer 12:93PubMedCentralCrossRefPubMed

Okuyama H, Endo H, Akashika T, Kato K, Inoue M (2010) Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 70:10213–10223CrossRefPubMed

Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, Shin SS, Choi YH, Park KJ, Park RW, Hwang SC (2006) Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11:269–275CrossRefPubMed

Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171:88–95CrossRefPubMed

Popowich DA, Vavra AK, Walsh CP, Bhikhapurwala HA, Rossi NB, Jiang Q, Aalami OO, Kibbe MR (2010) Regulation of reactive oxygen species by p53: implications for nitric oxide-mediated apoptosis. Am J Physiol Heart Circ Physiol 298:H2192–H2200PubMedCentralCrossRefPubMed

Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q, Ye Q (2012) Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med 29:832–840PubMed

Rabilloud T, Heller M, Rigobello MP, Bindoli A, Aebersold R, Lunardi J (2001) The mitochondrial antioxidant defence system and its response to oxidative stress. Proteomics 1:1105–1110CrossRefPubMed

Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11:1306–1313PubMedCentralCrossRefPubMed

Sena LA, Chandel NS (2012) Physiological roles of mitochondrial reactive oxygen species. Mol Cell 48:158–167PubMedCentralCrossRefPubMed

Shen C, Nathan C (2002) Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol Med 8:95–102PubMedCentralCrossRefPubMed

Shih SF, Wu YH, Hung CH, Yang HY, Lin JY (2001) Abrin triggers cell death by inactivating a thiol-specific antioxidant protein. J Biol Chem 276:21870–21877CrossRefPubMed

Singh M, Sharma H, Singh N (2007) Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. Mitochondrion 7:367–373CrossRefPubMed

Song IS, Kim HK, Jeong SH, Lee SR, Kim N, Rhee BD, Ko KS, Han J (2011) Mitochondrial peroxiredoxin III is potential target for cancer therapy. Int J Mol Sci 12:7163–7185PubMedCentralCrossRefPubMed

Srinivas P, Gopinath G, Banerji A, Dinakar A, Srinivas G (2004) Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog 40:201–211CrossRefPubMed

Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411–421PubMedCentralCrossRefPubMed

Tehan L, Taparra K, Phelan S (2013) Peroxiredoxin overexpression in MCF-7 breast cancer cells and regulation by cell proliferation and oxidative stress. Cancer Investig 31:374–384CrossRef

Tsuji K, Copeland NG, Jenkins NA, Obinata M (1995) Mammalian antioxidant protein complements alkylhydroperoxide reductase (ahpC) mutation in Escherichia coli. Biochem J 307:377–381PubMedCentralCrossRefPubMed

Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G (2009) Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer 125:264–275CrossRefPubMed

Wang XY, Wang HJ, Li XQ (2013) Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumour Biol 34:2275–2281CrossRefPubMed

Wang YG, Li L, Liu CH, Hong S, Zhang MJ (2014) Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells. Clin Transl Oncol 16:561–566CrossRefPubMed

Watabe S, Hiroi T, Yamamoto Y, Fujooka Y, Hasegawa H, Yago N, Takahashi SY (1997) SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. Eur J Biochem 249:52–60CrossRefPubMed

Whitaker HC, Patel D, Howat WJ, Warren AY, Kay JD, Sangan T, Marioni JC, Mitchell J, Aldridge S, Luxton HJ, Massie C, Lynch AG, Neal DE (2013) Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. Br J Cancer 109:983–993PubMedCentralCrossRefPubMed

Wonsey DR, Zeller KI, Dang CV (2002) The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 99:6649–6654PubMedCentralCrossRefPubMed

Woo HA, Jeong W, Chang TS, Park KJ, Park SJ, Yang JS, Rhee SG (2005) Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem 280:3125–3128CrossRefPubMed

Wu XY, Fu ZX, Wang XH (2010) Peroxiredoxins in colorectal neoplasms. Histol Histopathol 25:1297–1303PubMed

Xia LM, Huang WJ, Wang B, Liu M, Zhang Q, Yan W, Zhu Q, Luo M, Zhou ZZ, Tian DA (2009) Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J Cell Biochem 106:247–256CrossRefPubMed

Yamamoto T, Matsui Y, Natori S, Obinata M (1989) Cloning of a housekeeping-type gene (MER5) preferentially expressed in murine erythroleukemia cells. Gene 80:337–343CrossRefPubMed

Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, Semenza GL (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11:407–420CrossRefPubMed

Zhang B, Wang Y, Su Y (2009) Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286:154–160CrossRefPubMed

Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMed

Titel: The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells
verfasst von: Lianqin Li
Ai-Qun Yu
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-1916-3

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry

Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma

Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011

Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma

Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie